# US 2018/0021337 A1 · Salt of a pyrimido[6,1-a]isoquinolin-4-one compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021337 A1
- Document ID: US20180021337A1
- Status: Published application
- Kind: A1
- Application number: 15/549,500
- Filed: 2016-02-10
- Published: 2018-01-25
- Earliest claimed: 2015-02-11
- Assignees: Verona Pharma PLC
- Applicants: Verona Pharma PLC
- Inventors: Peter Lionel Spargo; Edward James French; Julian Scott Northen; John Mykytiuk
- Web page: https://patentgrep.com/patent/US20180021337A1

## CPC

- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 471/04: Ortho-condensed systems
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

## Claims

### Claim 1

A pharmaceutically acceptable acid addition salt of:
(i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and
(ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

### Claim 2 (depends on 1)

A pharmaceutically acceptable acid addition salt according to claim 1, wherein (ii) is ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, sulfuric acid or phosphoric acid.

### Claim 3 (depends on 1)

A pharmaceutically acceptable acid addition salt according to claim 1, which is selected from RPL554 ethane-1,2-disulfonate, RPL554 phosphate, RPL554 methanesulfonate, RPL554 ethanesulfonate, RPL554 hydrochloride, RPL554 sulfate, and solvates thereof.

### Claim 4 (depends on 1)

A pharmaceutically acceptable acid addition salt according to claim 1, which is RPL554 ethane-1,2-disulfonate.

### Claim 5 (depends on 1)

A pharmaceutically acceptable acid addition salt according to claim 1, which is RPL554 phosphate.

### Claim 6 (depends on 1)

A pharmaceutically acceptable acid addition salt according to claim 1, which is RPL554 methanesulfonate.

### Claim 7 (depends on 1)

A pharmaceutically acceptable acid addition salt according to claim 1, which is RPL554 hydrochloride.

### Claim 8 (depends on 1)

A pharmaceutically acceptable acid addition salt according to claim 1, which is RPL554 sulfate.

### Claim 9 (depends on 1)

A pharmaceutically acceptable acid addition salt according to claim 1, which is RPL554 ethanesulfonate.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition comprising a pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 9 and a pharmaceutically acceptable excipient, carrier or diluent.

### Claim 11 (depends on 10)

A pharmaceutical composition according to claim 10, which is formulated for administration by inhalation.

### Claim 12 (depends on 10, 11)

A pharmaceutical composition according to claim 10 or claim 11, which is a dry powder.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition according to claim 10 or claim 11, which is obtainable by dissolving a pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 9 in an aqueous solution.

### Claim 14 (depends on 13)

A pharmaceutical composition according to claim 13, wherein the aqueous solution is a buffered aqueous solution.

### Claim 15 (depends on 14)

A pharmaceutical composition according to claim 14, wherein the buffered aqueous solution comprises a phosphate buffer, a citrate buffer or a citro-phosphate buffer.

### Claim 16 (depends on 13, 14, 15)

A pharmaceutical composition according to any one of claims 13 to 15, wherein the pH of the pharmaceutical composition is greater than or equal to about 2.5.

### Claim 17 (depends on 13, 14, 15, 16)

A pharmaceutical composition according to any one of claims 13 to 16, wherein the pharmaceutically acceptable acid addition salt is present at a concentration of greater than or equal to about 1.0 mg/ml.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 9 for use in the treatment of the human or animal body.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 9 for use in the treatment or prevention of a disease or condition selected from asthma, allergic asthma, hay fever, allergic rhinitis, bronchitis, emphysema, bronchiectasis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), steroid resistant asthma, severe asthma, paediatric asthma, cystic fibrosis, lung fibrosis, pulmonary fibrosis, interstitial lung disease, skin disorders, atopic dermatitis, psoriasis, ocular inflammation, cerebral ischaemia, inflammatory diseases and auto-immune diseases.

### Claim 20 (depends on 19)

A pharmaceutically acceptable acid addition salt for use according to claim 19 wherein the disease or condition is chronic obstructive pulmonary disease (COPD).

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 20)

A method of treating or preventing a disease or condition as defined in claim 19 or claim 20 in a subject, which method comprises administering to said subject an effective amount of a pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 9.
